» Articles » PMID: 8289380

High-level Expression and Purification of Secreted Forms of Herpes Simplex Virus Type 1 Glycoprotein GD Synthesized by Baculovirus-infected Insect Cells

Overview
Journal J Virol
Date 1994 Feb 1
PMID 8289380
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Two forms of herpes simplex virus glycoprotein gD were recombined into Autographa californica nuclear polyhedrosis virus (baculovirus) and expressed in infected Spodoptera frugiperda (Sf9) cells. Each protein was truncated at residue 306 of mature gD. One form, gD-1(306t), contains the coding sequence of Patton strain herpes simplex virus type 1 gD; the other, gD-1(QAAt), contains three mutations which eliminate all signals for addition of N-linked oligosaccharides. Prior to recombination, each gene was cloned into the baculovirus transfer vector pVT-Bac, which permits insertion of the gene minus its natural signal peptide in frame with the signal peptide of honeybee melittin. As in the case with many other baculovirus transfer vectors, pVT-Bac also contains the promoter for the baculovirus polyhedrin gene and flanking sequences to permit recombination into the polyhedrin site of baculovirus. Each gD gene was engineered to contain codons for five additional histidine residues following histidine at residue 306, to facilitate purification of the secreted protein on nickel-containing resins. Both forms of gD-1 were abundantly expressed and secreted from infected Sf9 cells, reaching a maximum at 96 h postinfection for gD-1(306t) and 72 h postinfection for gD-1(QAAt). Secretion of the latter protein was less efficient than gD-1(306t), possibly because of the absence of N-linked oligosaccharides from gD-1(QAAt). Purification of the two proteins by a combination of immunoaffinity chromatography, nickel-agarose chromatography, and gel filtration yielded products that were > 99% pure, with excellent recovery. We are able to obtain 20 mg of purified gD-1(306t) and 1 to 5 mg of purified gD-1(QAAt) per liter of infected insect cells grown in suspension. Both proteins reacted with monoclonal antibodies to discontinuous epitopes, indicating that they retain native structure. Use of this system for gD expression makes crystallization trials feasible.

Citing Articles

A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1.

Egan K, Awasthi S, Tebaldi G, Hook L, Naughton A, Fowler B Viruses. 2023; 15(7).

PMID: 37515169 PMC: 10384700. DOI: 10.3390/v15071483.


Receptor Binding-Induced Conformational Changes in Herpes Simplex Virus Glycoprotein D Permit Interaction with the gH/gL Complex to Activate Fusion.

Atanasiu D, Saw W, Cairns T, Friedman H, Eisenberg R, Cohen G Viruses. 2023; 15(4).

PMID: 37112875 PMC: 10144430. DOI: 10.3390/v15040895.


Molecular determinants of the interaction between HSV-1 glycoprotein D and heparan sulfate.

Gandy L, Canning A, Lou H, Xia K, He P, Su G Front Mol Biosci. 2022; 9:1043713.

PMID: 36419932 PMC: 9678342. DOI: 10.3389/fmolb.2022.1043713.


Induction of Robust and Specific Humoral and Cellular Immune Responses by Bovine Viral Diarrhea Virus Virus-Like Particles (BVDV-VLPs) Engineered with Baculovirus Expression Vector System.

Wang Z, Liu M, Zhao H, Wang P, Ma W, Zhang Y Vaccines (Basel). 2021; 9(4).

PMID: 33917272 PMC: 8067437. DOI: 10.3390/vaccines9040350.


Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies.

Tuzmen C, Cairns T, Atanasiu D, Lou H, Saw W, Hall B Mol Ther Methods Clin Dev. 2020; 16:145-154.

PMID: 32042851 PMC: 7000558. DOI: 10.1016/j.omtm.2019.12.013.


References
1.
Varghese J, Laver W, Colman P . Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature. 1983; 303(5912):35-40. DOI: 10.1038/303035a0. View

2.
Johnson D, Burke R, Gregory T . Soluble forms of herpes simplex virus glycoprotein D bind to a limited number of cell surface receptors and inhibit virus entry into cells. J Virol. 1990; 64(6):2569-76. PMC: 249433. DOI: 10.1128/JVI.64.6.2569-2576.1990. View

3.
BERMAN P, Gregory T, Crase D, Lasky L . Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science. 1985; 227(4693):1490-2. DOI: 10.1126/science.2983428. View

4.
Smith G, Ju G, Ericson B, Moschera J, Lahm H, Chizzonite R . Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector. Proc Natl Acad Sci U S A. 1985; 82(24):8404-8. PMC: 390924. DOI: 10.1073/pnas.82.24.8404. View

5.
Zarling J, Moran P, Burke R, Pachl C, BERMAN P, Lasky L . Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD. J Immunol. 1986; 136(12):4669-73. View